Oct 15, 2004|
Ranbaxy: Global strategy on course
Ranbaxy Laboratories, India’s largest domestic pharma company, has reported a good topline growth of 12% during the September quarter. However, there was weakness seen in the bottomline growth, which grew by 7.5%. For the first nine months of CY04, the company registered a growth of 13% on consolidated basis in sales, basically driven by strong growth in the European, CIS, African and Latin American market.
Financial performance: A snapshot
Ranbaxy is the largest pharmaceutical company in India. Its annual sales nearly touched US$ 1 bn in the year 2003. It manufactures and markets branded generic pharmaceuticals products and Active Pharmaceutical Ingredients (APIs). It is a research driven company, with 6% of revenues going towards it. The continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Its foray into Novel Drug Delivery Systems has led to proprietary 'platform technologies' resulting in a number of products under development with one product Cipro OD in market. Ranbaxy's continued focus on European and US markets has helped it build deep product pipelines in both the markets. The company has about 127 ANDA filings out of which 92 have been approved by USFDA and 35 are awaiting approval. The company sells products in over 70 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 34 countries and manufacturing operations in 7 countries. The company's revenues have clocked a 24% CAGR in past five years, while the net profit has recorded a 42% CAGR.
|Operating profit (EBDITA)
|Operating profit margin (%)
|Profit before tax
|Profit after tax/(loss)
|Net profit margin (%)
|No. of shares (m)
|Diluted earnings per share (Rs)*
|P/E ratio (x)
US - Improving prospects:
Ranbaxy registered an impressive growth of 12% in the first nine months of CY04 on back of robust growth in European, CIS and Latin American markets. Looking into different geographies, the US still is the largest contributor to the topline (about 35%). Though US sales declined by 2% in the first nine months of the current year, the September quarter has recorded a growth of 12.5%, as the base effect of Cefuroxime Axetil is waning. If one removes the effect of this drug, the sales of the company have grown by 35% in first nine months of CY04 in the US. The total ANDA filings of the company in the US stood at 127 ANDAs, out of which 92 have been granted approval. The pipeline of the company is one of the largest in the US market, which indicates the potential growth prospect from this region in the form of new drug launches.
|What has driven performance in 9mCY04?|
Europe - Another big opportunity: In Europe the company’s performance was again exciting, with contribution from the French market coming in for the first time after the company acquired RPG Aventis, France. The European market grew by 107% with revenues of US$ 139 m. The French market is now the third largest for the company after US and India. The company has increased its regulatory filings to more than 14 products till date through various regulatory channels in Europe. With inclusion of 10 more countries in the European Union, Ranbaxy will be able to expand its market with the same regulatory approvals. Geographical mix
|India and Middle East
|Europe, CIS and Africa
|Allied Businesses *
Coming to India specifically, the company’s sales growth has tapered down to 5% in the September quarter. However, sales growth in first nine months has been impressive at 15%. The company is increasing focus on the fast growing lifestyle therapeutic segment. The share of lifestyle segment in the domestic sales of the company has increased to 36.5% from 34.0% last year. The over the counter (OTC) business of the company grew by 21%. One of its products 'Revital' has been ranked amongst top 10 brands in the domestic pharma market.
Operating margins: There has been a dip in the operating margins both in the September quarter as well as for the first nine months of the current year. While the operating margin of the company fell marginally in the quarter, the fall during the nine months was higher at 170 basis points. The fall can be attributed to higher staff and stock expenses. The company has increased its sales force in US markets to expand its branded formulations business in that region. However, falling revenues from highly profitable Cefuroxime Axetil have also contributed to the fall in the margins of the company (as realisations from the drug have come down). Operating margins are unlikely to change for the remainder of the year.
Net profits: Despite a strong YoY growth in topline, bottomline of the company grew by meager 3.5% during 9mCY04, mainly due to higher interest outgo. While the tax rate has come down to 24.4% in the current quarter from 27.6% last year, we expect a higher tax charge in the next quarter leading to depressed net margins in the last quarter of CY04.
At the current price of Rs 1,071, the stock trades at a P/E multiple of 25.4x annualised 9mCY04 earnings. The company has declared an interim dividend of Rs 5 per share. The company has expanded its presence in top generics markets globally. Ranbaxy's margins are likely to be subdued in the near term. Considering the fact that the pharma market is becoming global, and in light of the new WTO norms, companies like Ranbaxy with strong global presence will be able to benefit from this and grow in the long run. The company’s growth drivers will continue to be the US and the European markets. Going forward, Ranbaxy may see strong competition putting pressure on margins, which however, will be compensated by strong volume growth. Apart form that, R&D efforts of the company will also show benefits in the long run.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
TRACK RANBAXY LAB
- Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks